Shockwave Medical has announced CE mark regulatory approval for the company’s Lithoplasty balloon catheters for the treatment of peripheral artery disease.
Medtronic announced today (5 January 2015) that the FDA has approved the company’s IN.PACT Admiral drug-eluting balloon for the treatment of superficial femoral artery and popliteal artery lesions.
Roxwood Medical has announced FDA clearance for the US commercialisation of its CenterCross catheter for use in the coronary and peripheral vasculature.
ReFlow Medical has announced FDA clearance for US commercialisation of its SpeX shapeable support catheter for use in the peripheral vasculature and the first US clinical cases with the device.
The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s Savaysa (edoxaban), an oral, once-daily selective factor Xa inhibitor, to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Medtronic announced today that a previously communicated global voluntary recall to address an issue with certain lots of its Trellis-6 and Trellis-8 peripheral infusion systems has now been classified as a Class 1 recall by the US Food and Drug Administration (FDA).
Jafar Golzarian, SIR 2015’s programme chair, discusses some of the most exciting sessions from the Society of Interventional Radiology’s (SIR’s) upcoming Annual Scientific Meeting (28 February–5 March 2015, Atlanta, USA) for Interventional News.
Hansen has announced that an abstract accepted for presentation at the 40th Annual Society of Interventional Radiology (SIR) Meeting (28 February–5 March 2015, Atlanta, USA), has found that the use of the Magellan Robotic System in transarterial chemoembolization (TACE) procedures is feasible, and that remote robotic catheter navigation with Magellan leads to over 80% reduction in radiation dose to the operating physician when compared with a bedside control.
The results were presented at the seventh annual Symposium on Clinical Interventional Oncology (CIO, 31 January–5 February, Hollywood, USA), in collaboration with the International Symposium on Endovascular Therapy (ISET, 31 January–5 February, Hollywood, USA) by Ravi Murthy, Department of Interventional Radiology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, USA.
Combined data from more than 1,000 patients is being collected to assess the overall survival benefit of adding first-line SIR-Spheres Y-90 resin microspheres treatment to a current chemotherapy regimen for inoperable metastatic colorectal cancer.
Clinical work and data will be presented on Humacyte’s novel bioengineered blood vessel at the 27th International Symposium on Endovascular Therapy (ISET, 31 January–4 February, Hollywood, USA).
The Society of Interventional Radiology Foundation has released a statement announcing that the NIH-sponsored ATTRACT (Acute venous thrombosis: thrombus removal with adjunctive catheter-directed thrombolysis study) has completed accrual of its originally planned cohort of 692 patients.
Bariatric embolization is the first catheter-based procedure that attempts to directly address obesity. The minimally invasive technique is expected to decrease the hormone ghrelin, responsible for appetite, resulting in weight loss. Currently, the only proven long-term procedural solution for substantial weight loss is bariatric surgery, an often extensive operation.
The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched a new observational study that will gather data on patients with primary and secondary liver tumours treated with SIR‐Spheres microspheres at specialist hospitals across Europe.
CeloNova BioSciences has announced that it has received an expanded indication (CE mark) in Europe for its Embozene embolic microspheres to include the treatment of benign prostatic hyperplasia.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos